Introduction
Umbilical cord blood (UCB) from unrelated donors has been successfully used as an alternative hematopoietic stem cell source for treatment of hematologic malignancies in patients who do not have HLA-matched BM or PBSC donors. UCB transplantation (UCBT) has several advantages over BMT or PBSC transplantation (PBSCT) because of its rapid availability and lower risk of acute GVHD, even when there is a 1-3 HLA Ag mismatch. [1] [2] [3] [4] However, UCBT is associated with a higher risk of engraftment failure and more delayed immunological recovery than BMT and PBSCT. [5] [6] [7] [8] [9] [10] Recently, human herpesvirus-6 (HHV-6) has been recognized as an important pathogen in allogeneic hematopoietic SCT (HSCT). [11] [12] [13] [14] The reactivation of HHV-6 occurs around the time of neutrophil engraftment and occasionally causes limbic encephalitis, which is characterized by loss of short-term memory and abnormal hippocampal findings on magnetic resonance images. 15 Although limbic encephalitis due to HHV-6 used to be a rare complication after conventional HSCT, it is becoming one of the most serious complications after HSCT as the number of UCBT increases. 16, 17 HHV-6, a causal virus of infantile exanthem subitum, latently infects almost all Japanese adults. HHV-6 DNA is detected in the plasma of 33 to 48% of patients treated with HSCT, but is undetectable in plasma from healthy individuals or from UCB. 18, 19 HHV-6 DNA becomes detectable around day 9 or later after HSCT, and high HHV-6 DNA copy numbers are associated with development of BM suppression. [20] [21] [22] Foscarnet sodium (PFA) is thought to be preferable to ganciclovir as an anticytomegalovirus (CMV) drug used in the early posttransplant period because it has less BM toxicity than ganciclovir; 23 however, the safety of PFA administration early after HSCT has not been established in UCBT recipients. Ogata et al. 24 reported that the HHV-6 DNA copy number in the peripheral blood increased 100-fold within 3-4 days in some cases, and limbic encephalitis developed in UCBT recipients when the HHV-6 DNA copy number in plasma exceeded 1 Â 10 4 /mL. According to their report, once-a-week monitoring of HHV-6 DNA in plasma followed by preemptive administration of PFA was insufficient to prevent limbic encephalitis. More frequent monitoring of HHV-6 DNA such as three times a week, early after HSCT and preemptive administration of PFA on the basis of positive results, defined as a low viral copy number (5 Â 10 2 copy/mL), may help prevent HHV-6 encephalitis. To examine this hypothesis, we conducted a prospective, multicenter study of preemptive therapy of HHV-6 infection with low-dose PFA for high-risk patients after HSCT. This study documented the safety and efficacy of the preemptive administration of PFA in the prevention of severe HHV-6 encephalitis.
Methods

Endpoint of this study
This study was conducted primarily to assess the incidence of adverse events (AEs) associated with PFA administration until day 36 after HSCT because the safety of using PFA early after HSCT has not been established. The secondary endpoint was to assess the efficacy of preemptive administration of PFA in preventing the development of limbic encephalitis, as well as in reducing the amount of plasma HHV-6 DNA.
Study design
Eligible patients were aged from 16 to 75 years with hematologic disorders refractory to conventional therapy and were considered to require UCBT or HLA-1-haplotype-matched HSCT (haploidentical HSCT) from relatives due to the unavailability of an HLA-identical relative or a suitable unrelated donor. Informed consent was obtained from all subjects according to the Declaration of Helsinki, and this study protocol was approved by the institutional ethics committee (no. 5434). This trial was registered to the UMIN Clinical Trials Registry (UMIN-CTR; http://www. umin.ac.jp/ctr/index.htm) under identifier UMIN000001346. HLA matching was evaluated with molecular typing. Patients with high serum creatinine levels and/or lower estimated glomerular filtration rate greater than grade 2, and/or other organ dysfunctions greater than grade 3 defined by the Common Terminology Criteria ver.3.0 for Adverse Events (CTCAE) of the National Cancer Institute (USA), were excluded. Regimens for preconditioning and GVHD prophylaxis were not specified. The serum HHV-6 IgG titer before transplantation was determined by immunofluorescence assay. Peripheral blood samples were obtained every Monday, Wednesday and Friday from day 7 to day 36 after HSCT, and frozen plasma samples were sent to SRL Inc. (Tokyo, Japan) to measure the amount of HHV-6 DNA using a real-time PCR method on the following day. 25, 26 Administration of PFA, 90 mg/kg/day, was started on the day when the amount of plasma HHV-6 DNA exceeded 5 Â 10 2 copies/mL. The PFA dose was increased to 180 mg/kg/day when the plasma HHV-6 DNA copy number increased to more than 1 Â 10 5 /mL or when symptoms suggestive of encephalitis appeared. PFA was discontinued when the plasma HHV-6 DNA was negative on three consecutive occasions. If the patients' creatinine clearance fell below 1.4 mL/min/kg, the PFA dose was reduced according to the manufacturer's instructions.
Statistical analysis
The following variables related to patients and their clinical data were compared among the groups using Fisher's exact probability test or the Mann-Whitney U-test: gender (male versus female), HHV-6 IgG titer before HSCT, intensity of the conditioning regimen (myeloablative versus reducedintensity conditioning), prophylactic regimens for GVHD (cyclosporine-based versus tacrolimus-based), transplanted cell number, type of HSCT (UCBT versus haploidentical HSCT), date of WBCs 40.1 Â 10 9 /L, date of neutrophils 40.5 Â 10 9 /L, date of developing HHV-6 DNAemia (defined as the state characterized by the presence of HHV-6 DNA greater than 1 Â 10 2 copies/mL in plasma), duration of HHV-6 DNAemia and development of CMV antigenemia (positive versus negative). All P-values were two-sided, with values less than 0.05 being considered statistically significant. These analyses were performed using JMP ver. 7.0 (SAS Institute Inc., Cary, NC, USA). Table 1 ; their median age was 51 years (range 18-72 years). Eight patients received myeloablative preparative regimens and 13 patients received reduced-intensity conditioning before HSCT. Sixteen patients received a UCB graft, whereas five patients were grafted with PBSCs from HLAhaploidentical donors. GVHD prophylaxis regimens were cyclosporine in five patients and tacrolimus in 16 patients. All patients were seropositive for CMV without CMV disease before HSCT. One patient (UPN 2) who received PBSCT developed primary graft rejection due to anti-HLA class-I antibodies specific to a donor's mismatched allele and received second transplantation with UCB. This patient was re-registered as UPN 4. One UCBT patient (UPN 16) was excluded from the analysis because of early death (on day 4) after HSCT due to hepatic failure associated with primary biliary cirrhosis.
Results
Patients' characteristics
Toxicities of preemptive PFA administration
In 15 patients who received UCB grafts, AEs graded greater than 3 by CTCAE were observed in 7 of the 8 patients (88%) treated by PFA and 4 of the 7 patients (57%) not treated with PFA (Table 2a) . Most of these AEs associated with PFA treatment were electrolyte abnormalities such as hypernatremia, hypokalemia and hypomagnesemia (Table 2b ). These abnormalities improved promptly after appropriate fluid therapy. Severe renal dysfunction did not develop in any of the PFA-treated patients, although grade 2 renal dysfunction, such as a low glomerular filtration rate, was observed in two PFA-treated patients. Other grade 3 AEs included a transient rise in the aspartate aminotransferase level requiring no treatment and a systemic skin rash that disappeared after the administration of 100 mg hydrocortisone succinate. Four patients were dropped out of this study and died; two patients developed HHV-6 DNAemia not requiring PFA treatment and the other two patients remained negative for HHV-6 DNA during the observation period. The causes of death were hepatic veno-occlusive disease, bacteremia leading to pulmonary alveolar hemorrhage, thrombotic microangiopathy and bacteremia. Both attending physicians and central reviewers judged that there was no relationship between PFA administration and the causes of death in all four cases.
Development of HHV-6 DNAemia
Of the 15 UCBT recipients, 12 (80%) developed HHV-6 DNAemia. The HHV-6 DNA copy number exceeded 5 Â 10 2 /mL in 7 of the 11 patients; 1 patient (UPN 19) was erroneously treated with PFA when the HHV-6 copy number was less than 5 Â 10 2 /mL and was therefore excluded from this analysis. Conversely, all five haploidentical HSCT recipients remained negative for HHV-6 DNA in their plasma during the observation period (Po0.004). Therefore, further analyses focused on UCBT recipients. When the clinical characteristics were compared between patients positive for HHV-6 DNAemia (n ¼ 12) and those who did not develop HHV-6 DNAemia (n ¼ 3), on univariate analysis there were no significant differences in age, sex, HHV-6 IgG titer (tested in 11 cases), intensity of conditioning regimens, transplanted cell number, GVHD prophylactic regimens, date of WBCs 40.1 Â 10 9 /L and date of neutrophils 40.5 Â 10 9 /L (Table 3) . Table 4 shows the comparison of the characteristics of HHV-6 DNAemia between patients who eventually required PFA due to an increase in HHV-6 DNA copy number to greater than 5 Â 10 2 /mL and those who did not require PFA treatment after HSCT. In 6 of 7 treated patients, the HHV-6 DNA copy number was greater than 5 Â 10 2 copies/mL at the time when HHV-6 DNA was detected for the first time (median, 2.4 Â 10 3 copies/mL). Conversely, the HHV-6 DNA copy number was significantly lower in untreated patients at the time of the first HHV-6 DNA detection than in treated patients (median, 1.1 Â 10 2 copies/mL, P ¼ 0.01). HHV-6 DNAemia developed significantly later in patients who did not eventually require PFA treatment than in patients who required PFA treatment (median, day 22 versus day 17, Po0.02). The duration of HHV-6 DNAemia was significantly shorter in untreated patients than in the PFA-treated patients (median, 2 days versus 9 days, Po0.008). 
Abbreviations: AE ¼ adverse event; PFA ¼ foscarnet sodium; UCB ¼ umbilical cord blood. These adverse events were graded by the Common Terminology Criteria ver. 3.0 for Adverse Events (CTCAE) of the National Cancer Institute, USA. One patient who erroneously treated with PFA at under predetermined threshold was included in this analysis. Relationship between the time for neutrophil engraftment and that for the development of HHV-6 DNAemia Figure 1 illustrates the changes in the HHV-6 copy number in seven patients who required PFA administration. These patients achieved neutrophils 40. Effect of preemptive PFA administration PFA, 90 mg/kg/day, was administered to seven patients whose HHV-6 DNA copy number exceeded 5 Â 10 2 copies/ mL from day 15 to day 20 (median, day 17) after UCBT. The amount of HHV-6 DNA in the plasma decreased on the next day of PFA administration in 4 of the 7 patients, whereas three other patients required 3-4 days until the copy number decreased (Figure 1, red arrows) . In two patients, the HHV-6 DNA copy numbers exceeded 1 Â 10 4 / mL (UPN 1 and UPN 21) , a level that predicts the development of limbic encephalitis, on the next day of first PFA administration with no symptoms suggestive of encephalitis, and the HHV-6 DNA copy number decreased 3-4 days after PFA administration. Of 15 patients who achieved neutrophil engraftment after HSCT, 4 of 7 patients who did not receive PFA developed CMV antigenemia within 60 days after HSCT, whereas no patients treated with PFA developed CMV antigenemia (Po0.03).
Limbic encephalitis developed in one patient (UPN 9) who received preemptive PFA administration. This patient showed an increase in the HHV-6 DNA copy number on day 17 after UCBT ( Figure 2 ). When the first PFA administration was started at 2000 hours on day 18 by 3-h intravenous drip infusion, there were no neurological symptoms. The patient was found to be unconscious at his bedside around 2300 hours during the PFA infusion. A magnetic resonance study showed asymmetric Table 4 Characteristics of HHV-6 DNAemia-positive UCBT recipients and their HHV-6 DNAemia One patient who was erroneously treated with PFA at under the predetermined threshold was excluded in this analysis.
Table 3
Comparison of clinical features between HHV-6 DNAemia positive and negative patients in UCBT recipients 
Discussion
PFA has been used for the treatment of HHV-6 encephalitis; [27] [28] [29] however, the safety of initiating the administration of PFA before neutrophil engraftment has not been established. Although PFA administration is not usually associated with BM suppression, it may impair UCB engraftment when it is used soon after transplantation. Furthermore, PFA frequently causes renal dysfunction. Two papers described the effectiveness and safety of lowdose PFA treatment for CMV infection after HSCT, 23, 30 but little is known about the toxicity and the efficacy of its administration in the early period after HSCT so far because most patients received PFA treatment on day 30 or later. Previous studies documented that HHV-6 DNAemia developed as early as day 15 after UCBT. 17 One of our patients (UPN 21) developed HHV-6 DNAemia, with a copy number of 7.3 Â 10 3 /mL on day 10 after UCBT. Therefore, it is necessary to confirm the safety of the use of anti-HHV-6 agents before neutrophil engraftment. This study showed that low-dose PFA could be administered to UCBT recipients with acceptable toxicities even in the very early period after HSCT. Greater than grade-3 AEs occurred in 7 of 8 PFA-treated patients and 4 of 7 PFA-untreated patients, and there appears to be a tendency toward a higher incidence of severe AEs in PFA-treated patients than in untreated patients. However, the total number of AEs greater than grade 3 that occurred in the eight PFA-treated patients was 8, similar to the 6 in the 7 untreated patients. A skin rash developed on day 17 and day 20, just before starting PFA treatment in two patients. Because it disappeared quickly with PFA treatment, the rash may have been associated with HHV-6 reactivation. 31, 32 Several risk factors have been identified for HHV-6 reactivation after HSCT. These include younger age, treatment with steroid, low titers of anti-HHV-6 IgG before HSCT and development of GVHD. 14, 24, 33, 34 The use of transplantation from alternative graft sources, such as HLA-mismatched BM and UCB, is another risk factor for HHV-6 reactivation. 24, [34] [35] [36] In this study, UCBT was more associated with HHV-6 reactivation than haploidentical PBSCT. Of note, none of the patients who enrolled in this study developed acute GVHD and required corticosteroid treatment as a result, except for short-acting corticosteroids given to ameliorate fever or allergic symptoms. It is conceivable that PFA administration with this dosage may mitigate the secretion of inflammatory cytokines such as IFN-g or TNF-a from immune cells by inhibiting HHV-6 reactivation. This possibility needs to be examined in a prospective study involving a larger number of patients.
Two groups have documented the favorable results of prophylactic ganciclovir administration for HHV-6 infection after neutrophil engraftment. 37, 38 In this study, 5 of the 7 patients whose DNA copy number later exceeded 5 Â 10 for other strategies for preventing HHV-6 infection, because ganciclovir is associated with BM suppression. This study showed that the earlier the reactivation occurred, the more the increase in the HHV-6 viral load; the viral load increased within 48 h after the negative test to a level greater than 5 Â 10 2 /mL. Thus, it may be important to ensure that the test result for HHV-6 DNA measurement can be returned on the day of blood sampling, or at least by the following morning, to make the preemptive approach successful. However, most hospitals are unable to get results in this short time. It is possible that prophylactic PFA administration before the time of leukocyte recovery would be a more reasonable approach rather than preemptive PFA administration after the identification of HHV-6 DNA.
To prevent limbic encephalitis, what needs to be treated with PFA is HHV-6 DNAemia that occurs before the rise in the leukocyte count. Therefore, prophylactic administration of PFA from day 7 or earlier to day 20 may be a more reasonable approach than preemptive PFA administration guided by HHV-6 DNA detection to prevent limbic encephalitis in UCBT recipients. The efficacy of such prophylactic administration of PFA after UCBT is now being examined in a prospective study.
